Form 4: Myriad Genetics Executive Mark Verratti Reports Stock Transaction
SEC Form 4 Filing
Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On April 14, 2025, Mark Verratti, the Chief Commercial Officer of Myriad Genetics Inc., had 1,085 shares of common stock withheld by the company to cover tax obligations.
- This transaction occurred in connection with the vesting of restricted stock units.
- The price per share was $8.08.
- Following the transaction, Verratti directly owns 382,911 shares of Myriad Genetics Inc.
- The transaction was reported on April 15, 2025.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a routine stock transaction, indicating a neutral sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects an executive's stock ownership and compensation.
Key Dates
| Date | Description |
|---|---|
| 04/14/2025 | Date of stock transaction (shares withheld for tax obligations). |
| 04/15/2025 | Date of Form 4 filing. |
Keywords
Form 4, Myriad Genetics, Stock Transaction, Beneficial Ownership, Verratti, MYGN, Tax Withholding, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.